(Total Views: 579)
Posted On: 01/24/2020 11:50:15 AM
Post# of 148878
I emailed NP about the CCR+ status of her cancer today since, I was not sure he had mentioned it. This was his response.
Thank you xxxx. My mother-in-law’s cancer is HER2+ and she has CCR5+ in leucocytes infiltrating around the tumor and had no CCR5 on the tumor.
With best regards
Nader
Although the N=1, this may be significant if confirmed in other patients.
Another relating to the NK (NantkWest) discussion last week. I believe for that therapy, the patients have to come into the hospital/clinic twice a week for IV cell infusions. Leronlimab is SQ self injectable at home once week. Happy to see patients having lots of options, but convenience may help with compliance and, therefore, overall success also.
One more point, monoclonal ABs can often be manufactured for about 1$ a vial, once manufacturing is fully up to scale. Cell/Infusion based therapies may not be as readily scalable.
All above IMO only.
Thank you xxxx. My mother-in-law’s cancer is HER2+ and she has CCR5+ in leucocytes infiltrating around the tumor and had no CCR5 on the tumor.
With best regards
Nader
Although the N=1, this may be significant if confirmed in other patients.
Another relating to the NK (NantkWest) discussion last week. I believe for that therapy, the patients have to come into the hospital/clinic twice a week for IV cell infusions. Leronlimab is SQ self injectable at home once week. Happy to see patients having lots of options, but convenience may help with compliance and, therefore, overall success also.
One more point, monoclonal ABs can often be manufactured for about 1$ a vial, once manufacturing is fully up to scale. Cell/Infusion based therapies may not be as readily scalable.
All above IMO only.
(3)
(0)Scroll down for more posts ▼
